Drug Trials News for November 2009

AFFiRiS AG moves Alzheimer’s vaccine candidate into clinical Phase II testing

AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010.
19 November, 2009

Astex announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387

Astex Therapeutics Limited recently announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to collaborate on the study of its novel small-molecule HSP90 inhibitor, AT13387, for the treatment of cancer.
06 November, 2009

CureVac launches Phase IIa mRNA vaccine trial in prostate cancer

This will be the first evaluation of CureVac's RNActive® vaccine technology in humans.
05 November, 2009

Drug Trials News Archive

AFFiRiS AG moves Alzheimer’s vaccine candidate into clinical Phase II testing AFFiRiS AG moves Alzheimer’s vaccine candidate into clinical Phase II testing

Astex announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387 Astex announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387

CureVac launches Phase IIa mRNA vaccine trial in prostate cancer CureVac launches Phase IIa mRNA vaccine trial in prostate cancer

AFFiRiS AG moves Alzheimer’s vaccine candidate into clinical Phase II testing

Astex announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387

CureVac launches Phase IIa mRNA vaccine trial in prostate cancer